Earlier this week, FDA staffers recommended that Xarelto should not be marketed withoutmore data, mainly because of questions about the control group in its key study.
Indeed, the restructuring of the chaebol has slowed down recently, partly because their autocratic chairmen cannot raise much more capital on the booming stockmarket without endangering the control of their empires, which they are loth to do.